Updated time: 2024-07-11 10:53:32
03A-1100630
2021-10-07
TW I 847260
Protein misfolding and aggregation play important roles in neurodegenerative disease. To reduce toxicity from aggregated proteins, we designed a series of proteolysis targeting chimeric compounds (PROTACs) for use in prevention and treatment of neurodegenerative diseases. In one example of this invention, the PROTAC comprises an E3-ligase recruiting ligand and an aggregated protein binding ligand connected by a linker. In one embodiment, the PROTAC reduces the TDP-43 C-terminal fragment (C-TDP-43) aggregates and oligomers toxicity in amyotrophic lateral sclerosis (ALS) related cell model and C. elegans animal model. In another embodiment, we use PROTAC to degrade the protein aggregates that cause Huntington’s disease. Hyperphosphorylated Tau protein is a major hallmark of Alzheimer’s disease and many other neurological disorders. In one example of this invention, we use PROTAC to degrade the pathogenic Tau protein.
- So far, no drug can directly eliminate abnormal protein aggregates. The catalytic mode of PROTAC allows a PROTAC molecule to eliminate the target protein by inducing ubiquitination. This mechanism can be repeated many times. Compared with the traditional method of using inhibitors, PROTAC can eliminate the target protein with fewer chemical doses to improve efficacy and avoid adverse side effects. The PROTACs of this invention are small molecules, which can directly eliminate pathogenic protein aggregates and have advantages in mass production, pharmacokinetics and pharmacodynamics verification.
- Amyotrophic lateral sclerosis (ALS)
- Frontotemporal dementia (FTD)
- Alzheimer’s disease (AD)
- Huntington’s disease (HD)
- Parkinson’s disease (PD)

Fig1. Mechanism for protein aggregates degradation by PROTAC: The PROTAC binds E3 ligase and protein aggregates (e.g. TDP-43) simultaneously to facilitate the transfer of ubiquitins to protein aggregates. As ubiquitin chains on protein aggregates are recognized by proteasome, protein aggregates are degraded.
Joseph Jen-Tse Huang, Jim-Min Fang, Yijuang Chern, Yu-Ling Tseng, Yung-An Huang
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

PROTEOLYSIS-TARGETING CHIMERIC COMPOUNDS FOR DEGRADATION OF NEURODEGENERATIVE DISEASE-RELATED PROTEIN AGGREGATES